Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
All IDC research is © 2015 by IDC. All rights reserved. All IDC materials are licensed with IDC's permission and in no way does the use or publication of IDC research indicate IDC's endorsement of Dassault Système’s products/or strategies.
AN IDC INFOGRAPHIC, SPONSORED BY DASSAULT SYSTÈMES
Life Sciences Research
Challenges Facing the Research Ecosystem
Life Sciences Industry Goals
Why Biologics is Increasingly Important
BIOVIA Biologics for Discovery, Development and Manufacturing
The R&D ecosystem is becoming increasingly complex
It’s getting harder to:
Quality
51%
Efficiency InnovationReduce variability in
processes and products;quality by design for
better process understanding
Harmonization, standardization,
integration,externalization
Global collaboration, new technologies,
knowledge management, shift toward biologics
Reasons for growth:
Users report up to 50% gains in efficiency and throughput, as well as improved quality of results with this type of solution.
Learn more about challenges facing biologics discovery researchers and product developers, and Dassault Systèmes' BIOVIA Biologics solution, by downloading the IDC white paper, "Looking
Forward: The Case for Intelligent Design (and Infrastructure) in Life Science Biologics R&D.”
Intelligent Infrastructure for
Access new research
capabilities
Work well with global
teams
Pick the right tool for the right task Visualize and
share complex models
Standardize experimentation
Share and transfer data internally and externally
Leverage rapid growth of data,
information, and knowledge
Superior efficacy
Premium pricing
12-year exclusivity (U.S.)Satisfies previously unmet clinical
needs
Discoveryand Analysis
Registrationand Sample
Management
PredictiveAnalytics
ProcessProductionOperations
WorkflowSupport
RegulatoryQuality
Compliance
BioprocessDocumentation
and DataManagement
BIOVIAFOUNDATION
of the top 100 prescription and OTC drug sales will be biologics by 2018*
*EvaluatePharma
6of the top-selling drugs in 2014 were biologics*